Mechanisms of inhibitors of mutagenesis and carcinogenesis

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 402, Issue 1-2, 1998, Pages 151-158

  De Flora, Silvio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Anticarcinogenesis; Antimutagenesis; Chemoprevention; Inhibitor; Mechanism

Indexed keywords

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER PREVENTION; CARCINOGENESIS; CONFERENCE PAPER; DRUG MECHANISM; HUMAN; MUTAGENESIS; MUTATION; PRIORITY JOURNAL;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTIMUTAGENIC AGENTS; HUMANS;

EID: 0032543429     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(97)00292-3     Document Type: Conference Paper

References (47)

1. [1] S. De Flora, A. Izzotti, K. Randerath, E. Randerath, H. Bartsch, J. Nair, R. Balansky, F. van Schooten, P. Degan, G. Fronza, D. Walsh, J. Lewtas, DNA adducts and chronic degenerative diseases. Pathogenetic relevance and implications in preventive medicine, Mutat. Res. 366 (1996) 197-238.
2. [2] S. De Flora, G. Bronzetti, F.H. Sobels (Eds.), Assessment of antimutagenicity and anticarcinogenicity. End-points and systems. Mutat. Res. 267 (1992) 153-295.
3. [3] G.J. Kelloff, C.W. Boone (Eds.), Cancer chemopreventive agents: drug development status and future prospects. J. Cell Biochem., Suppl. 20 (1994) 1-303.
4. [4] S. De Flora, C. Ramel, Mechanisms of inhibitors of mutagenesis and carcinogenesis. Classification and overview, Mutat. Res. 202 (1988) 285-306.
5. [5] S. De Flora, R. Balansky, L. Scatolini, C. Di Marco, L. Gasparini, M. Orlando, A. Izzotti, Adducts to nuclear DNA and mitochondrial DNA as biomarkers in chemoprevention, in: B.W. Stewart, D. McGregor, P. Kleihues (Eds.), Principles of Chemoprevention, IARC Sci. Publ. No. 139, International Agency for Research on Cancer, Lyon, France, (1996) pp. 291-301.
6. [6] S. De Flora, Proposed classification of inhibitors of mutagenesis and carcinogenesis according to their mechanisms (Abstract). 2nd Intern. Conf. on Anticarcinogenesis and Radiation Protection, Gaithersburg, MD, USA, March 8-12, (1987).
7. [7] S. De Flora, Mechanisms of inhibitors of genotoxicity. Relevance in preventive medicine, in: M.L. Mendelsohn, R.J. Albertini (Eds.), Mutation and the Environment, Part E, Wiley-Liss, New York, NY (1990) pp. 307-318.
8. [8] S. De Flora, P. Zanacchi, A. Izzotti, H. Hayatsu, Mechanisms of food-borne inhibitors of genotoxicity relevant to cancer prevention, in: H. Hayatsu (Ed.), Mutagens in Food. Detection and Prevention, CRC Press, Boca Raton, FL, USA (1991) pp. 157-180.
9. [9] S. De Flora, A. Izzotti, C. Bennicelli, Mechanisms of antimutagenesis and anticarcinogenesis. Role in primary prevention, in: G. Bronzetti, H. Hayatsu, S. De Flora, M.D. Waters, D.M. Shankel (Eds.), Antimutagenesis and Anticarcinogenesis Mechanisms III, Plenum, New York, NY, (1993) pp. 1-16.
10. [10] S. De Flora, Cancer prevention strategies and mechanisms of chemopreventive agents, Eur. J. Cancer Prev. 3 (1994) 364-366.
11. [11] S. De Flora, R. Balansky, C. Bennicelli, A. Camoirano, F. D'Agostini, A. Izzotti, C.F. Cesarone, Mechanisms of anticarcinogenesis: the example of N-acetylcysteine, in: C. Ioannides, D.F.V. Lewis (Eds.), Drugs, Diet and Disease, Vol. 1. Mechanistic Approaches to Cancer, Ellis Horwood, Hemel Hempstead, UK (1995) pp. 151-203.
12. [12] J. Trosko, C. Chang, An integrative hypothesis linking cancer, diabetes, and atherosclerosis: the role of mutations and epigenetic changes, Med. Hypotheses 6 (1980) 455-468.
13. [13] M.W. Majesky, M.A. Reidy, E.P. Benditt, M.R. Juchau, Focal smooth muscle proliferation in the aortic intima produced by an initiation-promotion sequence, Proc. Natl. Acad. Sci. U.S.A. 82 (1985) 3450-3454.
14. [14] L.W. Wattenberg, Inhibitors of chemical carcinogens, in: J.H. Burchenal, H.F. Oettgen (Eds.), Cancer: Achievements, Challenges and Prospects for the 1980s, Grune and Stratton, New York, NY (1981) pp. 517-540.
15. [15] M.A. Morse, G.D. Stoner, Cancer chemoprevention: principles and prospects, Carcinogenesis 14 (1993) 1737-1746.
16. [16] C. Ramel, U.K. Alekperov, B.N. Ames, T. Kada, L.W. Wattenberg, Inhibitors of mutagenesis and their relevance to carcinogenesis, Mutat. Res. 168 (1986) 47-65.
17. [17] T. Kada, T. Inoue, N. Namiki, Environmental desmutagens and antimutagens, in: E.J. Klekowski (Ed.), Environmental Mutagenesis and Plant Biology, Praeger, New York (1982) pp. 137-151.
18. [18] E.R. Fearon, B. Volgstein, A genetic model for colorectal tumorigenesis, Cell 61 (1990) 759-767.
19. [19] C.W. Boone, G.J. Kelloff, V.E. Steele, Natural history of intraepithelial neoplasia in humans with implications for cancer chemopreventive strategy, Cancer Res. 52 (1992) 1651-1659.
20. [20] G.J. Kelloff, C.W. Boone, V.E. Steele, J.A. Crowell, R. Lubet, C.C. Sigman, Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials, Cancer Res. 54 (Suppl.) (1994) 2015s-2024s.
21. [21] P. Greenwald, G.J. Kelloff, C.W. Boone, S.S. McDonald, Genetic and cellular changes in colorectal cancer: proposed targets of chemopreventive agents, Cancer Epidemiol. Biom. Prev. 4 (1995) 691-702.
22. [22] G.J. Kelloff, C.W. Boone, V.E. Steele, J.A. Crowell, R.A. Lubet, P. Greenwald, E.T. Hawk, J.R. Fay, C.C. Sigman, Mechanistic considerations in the evaluation of chemopreventive data, in: B.W. Stewart, D. McGregor, P. Kleihues (Eds.), Principles of Chemoprevention, IARC Sci. Publ. No. 139, International Agency for Research on Cancer, Lyon, France (1996) pp. 203-219.
23. [23] J.S. Bertram, L.N. Kolonel, F.L. Meyskens Jr., Rationale and strategies for chemoprevention of cancer in humans, Cancer Res. 47 (1987) 3012-3031.
24. [24] H. Bartsch, H. Ohshima, B. Pignatelli, Inhibitors of endogenous nitrosation. Mechanisms and implications in human cancer prevention, Mutat. Res. 202 (1988) 307-324.
25. [25] T. Tanaka, T. Shinoda, N. Yoshimi, K. Niwa, H. Iwata, H. Mori, Inhibitory effect of magnesium hydroxide on methylazoxymethanol acetate-induced large bowel carcinogenesis in male F344 rats, Carcinogenesis 10 (1989) 613-616.
26. [26] P.E. Hartman, D.M. Shankel, Antimutagens and anticarcinogens: a survey of putative interceptor molecules, Environ. Mol. Mutagen. 151 (1990) 145-182.
27. [27] S. Arimoto, K. Kan-yama, H. Rai, H. Hayatsu, Inhibitory effect of hemin, clorophyllin and related pyrrole pigments on the mutagenicity of benzo[a]pyrene and its metabolites, Mutat. Res. 345 (1995) 127-135.
28. [28] T. Minoura, T. Takata, M. Sakaguchi, H. Takada, M. Yamamura, K. Hioki, M. Yamamoto, Effect of dietary eicosapentaenoic acid on azoxymethane-induced colon carcinogenesis in rats, Cancer Res. 48 (1988) 4790-4794.
29. [29] R. Cozzi, P. Perticone, R. Bona, S. Polani, Antimutagenic activities of naturally occurring polyamines in Chinese Hamster ovary cells in vitro, Environ. Mol. Mutagen. 18 (1991) 207-211.
30. [30] H. Hibasami, T. Tsukada, S. Maekawa, M. Sakurai, K. Nakashima, Inhibition of mouse skin tumour promotion and of promoter-induced epidermal polyamine biosynthesis by methylglyoxal bis(butylamidinohydrazone), Carcinogenesis 9 (1988) 199-202.
31. [31] A.M. Shamsuddin, A. Ullah, Inositol hexaphosphate inhibits large intestinal cancer in F344 rats 5 months after induction by azoxymethane, Carcinogenesis 10 (1989) 625-626.
32. [32] X.M. Gao, E.M. Perchellet, A.W. Davis, S.W. Newell, D.H. Hua, J.-P. Perchellet, Characterization of the antitumour-promoting activity of camptothecin in SENCAR mouse skin, Carcinogenesis 17 (1996) 1141-1148.
33. [33] C. Hélène, Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides, Eur. J. Cancer 27 (1991) 1466-1471.
34. [34] Y. Choo, I. Sánchez-García, A. Klug, In vivo repression by site-specific DNA-binding protein designed against an oncogenic sequence, Nature 372 (1994) 642-645.
35. [35] J.R. Bischoff, D.H. Kirn, A. Williams, C. Heise, S. Horn, M. Muna, L. Ng, J.A. Nye, A. Sampson-Johannes, A. Fattaey, F. McCormick, An adenovirus mutant that replicates selectively in p53-deficient human tumor cells, Science 274 (1996) 373-376.
36. [36] G.B. Pierce, W.C. Speers, Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation, Cancer Res. 48 (1988) 1996-2004.
37. 2/M arrest in keratinocytes, Carcinogenesis 17 (1996) 2367-2375.
38. [38] I.B. Weinstein, Strategies for inhibiting multistage carcinogenesis based on signal transduction pathways, Mutat. Res. 202 (1988) 413-420.
39. [39] Y. Cho-Chung, Role of cyclic AMP receptor proteins in growth, differentiation and suppression of malignancy: new approaches to therapy, Cancer Res. 50 (1990) 7093-7100.
40. [40] B.E. Henderson, R.K. Ross, M.C. Pike, Hormonal chemoprevention of cancer in women, Science 259 (1993) 633-638.
41. [41] R. Lathe, M.P. Kieny, P. Gerlinger, P. Clertant, I. Guizani, F. Cuzin, P. Chambon, Tumour prevention and rejection with recombinant vaccinia, Nature 326 (1987) 878-880.
42. [42] D. Giunciuglio, T. Cai, L. Masiello, S. De Flora, A. Albini, N-Acetylcysteine. A possible inhibitor of tumor angiogenesis (Abstract). In: Oxidative Stress and Redox Regulation, Paris, France, 21-24 May 1996.
43. [43] G. Gasparini, Angiogenesis research up to 1996. A commentary on the state of art and suggestions for future studies, Eur. J. Cancer 32A (1996) 2379-2385.
44. [44] P. Mignatti, D.B. Rifkin, Plasminogen activators and matrix metalloproteinases in angiogenesis, Enzyme Protein 49 (1996) 117-137.
45. [45] A. Albini, F. D'Agostini, D. Giunciuglio, I. Paglieri, R. Balansky, S. De Flora, Inhibition of invasion, gelatinase activity, tumor take and metastasis of malignant cells by N-actylcysteine, Int. J. Cancer 61 (1995) 121-129.
46. [46] W.G. Stetler-Stevenson, R. Hewitt, M. Corcoran, Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic, Semin. Cancer Biol. 7 (1996) 147-154.
47. [47] P.L. Lollini, C. De Giovanni, L. Landuzzi, G. Nicoletti, F. Frabetti, F. Cavallo, M. Giovarelli, G. Forni, A. Modica, A. Modesti, Transduction of genes coding for a histocompatibility (MHC) antigen and for its physiological inducer interferon-gamma in the same cell: efficient MHC expression and inhibition of tumor and metastasis growth, Hum. Gene Ther. 6 (1995) 743-752.